Relationship between programmed cell death and targeted therapy for thyroid cancer in patients with a poor prognosis: an update

程序性细胞死亡与甲状腺癌靶向治疗在预后不良患者中的关系:最新进展

阅读:1

Abstract

In recent years, the incidence of thyroid cancer has steadily increased. However, the detailed mechanisms of pathogenesis are still unclear. Therefore, a comprehensive understanding of the underlying carcinogenesis mechanisms of thyroid cancer is required. Programmed cell death (PCD) is a cell death process mediated by specific molecular program, regulated by specific genes within the cell. Accumulating evidence suggests that PCD plays an indispensable role in thyroid cancer, maintaining intracellular stability by regulating genes and eliminating damaged or aged cells. In this review, we summarize six identified forms of PCD, analyze biomarkers for different PCD pathways in thyroid cancer, and briefly elucidate the roles of various PCD pathways in targeted therapies for thyroid cancers with a poor prognosis. We also provide an outlook on future treatments for drug-resistant thyroid cancer, poorly differentiated thyroid cancer, and iodine-refractory thyroid cancer, aiming to accurately identify targets and offer effective targeted therapeutic strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。